Neurogene Inc (NGNE) FinancialsNGNENeurogene Inc

Evaluating the bottom line, Neurogene Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.32%, provide a clear picture of how effectively NGNE converts its operational activities into shareholder value.

In the context of the broader market, NGNE competes directly with industry leaders such as MNPR and ARVN. With a market capitalization of $479.27M, it holds a significant position in the sector. When comparing efficiency, NGNE's gross margin of N/A stands against MNPR's N/A and ARVN's 96.40%. Such benchmarking helps identify whether Neurogene Inc. is trading at a premium or discount relative to its financial performance.

Neurogene has shown significant net losses, with a net income of -34,488,000 USD in Q2 2026, and a negative EPS of -1.53, indicating ongoing financial challenges. However, it maintains a strong current ratio of 10.64, suggesting good short-term liquidity.